Gabather enters into a research collaboration with leading US scientists to investigate GT-002 in a unique preclinical model of Alzheimer’s Disease
Gabather AB (Nasdaq First North Growth Market: GABA) today announces the establishment of a research collaboration with Massachusetts General Hospital to investigate the effect of its drug candidate GT-002 in a preclinical model of Alzheimer’s disease. The first stages of the clinical development (single and multiple ascending doses) with GT-002 has recently been successfully completed, paving the way for the development of the drug candidate in a broad range of mental disorders.Gabather has signed an agreement with Massachusetts General Hospital, where Dr Kastanenka, Assistant Professor of